Table 2.
Comparison of Tumor and Cycle Characteristics of Women With BRCA Gene Mutations
| BRCA-Positive COSTLES FP, %, or Mean ± SD (n = 26) | BRCA-Positive Control, %, or Mean ± SD (n = 21) | P Value | |
|---|---|---|---|
| Age at cancer diagnosis, y | 31.8 ± 3.8 | 33.8 ± 3.3 | .08 |
| BMI, kg/m2 | 22.0 ± 2.5 | 20.5 ± 2.1 | .23 |
| Tumor size, cm | .02 | ||
| <2 | 65 | 58 | |
| ≥2 | 35 | 42 | |
| Lymphovascular space invasion | 38 | 43 | .85 |
| ER positive | 43 | 53 | .55 |
| Progesterone receptor positive | 38 | 50 | .49 |
| HER-2/neu positive | 15 | 30 | .33 |
| Adjuvant tamoxifen use | 75 | 57 | .46 |
| Length of follow-up, y | 4.7 ± 2.7 | 6.9 ± 4.3 | .06 |
Abbreviation: BMI, body mass index.